← Leaderboards
Elliot Israel
Brigham And Women'S Hospital
$35,880,602
Attributed
$57,223,731
Total exposure
21
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $9.6M · FY2005–23$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$56,142,601 · 21
AHRQ$10,065,165 · 2
By mechanism
U01$23,527,406 · 2
U10$18,338,668 · 4
R01$13,083,571 · 3
U19$4,625,778 · 4
P50$3,803,230 · 2
UG1$2,792,447 · 1
Top collaborators
- Bruce D Levy16 shared
- Mario Castro8 shared
- Suzy Comhair8 shared
- Loren C Denlinger8 shared
- Eric A Hoffman8 shared
- Purveshkumar Khatri8 shared
- David T Mauger8 shared
- Deborah A. Meyers8 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Joshua A Boyce$54,050,346
- Nora Amanda Barrett$12,519,597
- Steven A Shea$17,974,788
- Y. Shrike Zhang$13,550,158
- Junjie Yao$7,353,492
Others in their field
Top investigators on “Asthma”
- James E. Gern · University Of Wisconsin-Madison$159,588,264
- William W. Busse · University Of Wisconsin Madison$104,093,792
- Scott T Weiss · University Of California, San Diego$98,211,117
- David T Mauger · Pennsylvania State Univ Hershey Med Ctr$79,309,576
- Fernando D Martinez · University Of Arizona$66,357,737
- Wanda Phipatanakul · Boston Children'S Hospital$50,505,446
Research focus
AsthmaInflammationResponseCellsClinical ResearchMorbidity - Disease RateReceptorRespiratoryInflammatorySignal TransductionAdrenal Cortex HormonesClinical TrialsMediatingAirway InflammationSputumBaseCohortLungPhenotypeHuman SubjectDefectAdultProductionMonitor
Grant awards (74)
Immunometabolic phenotypes in adult severe asthma and disease progression$3,233,979
U01 · FY2023 · HL
Immunometabolic phenotypes in adult severe asthma and disease progression$216,239
U01 · FY2023 · HL
Immunometabolic phenotypes in adult severe asthma and disease progression$3,322,614
U01 · FY2022 · HL
PATINA - Precision Administration of Treatment in Neutrophilic severe Asthma$434,253
UG1 · FY2022 · HL · contact PI
Rapid saliva antigen test for SARS-CoV-2 detection$434,002
U01 · FY2022 · HL
Immunometabolic phenotypes in adult severe asthma and disease progression$235,989
U01 · FY2022 · HL
Immunometabolic phenotypes in adult severe asthma and disease progression$3,058,207
U01 · FY2021 · HL
PATINA - Precision Administration of Treatment in Neutrophilic severe Asthma$481,316
UG1 · FY2021 · HL · contact PI
Immunometabolic phenotypes in adult severe asthma and disease progression$3,355,708
U01 · FY2020 · HL
PATINA - Precision Administration of Treatment in Neutrophilic severe Asthma$482,469
UG1 · FY2020 · HL · contact PI
Project 3: Therapeutic Control of AERD$460,159
U19 · FY2020 · AI · contact PI
Project 3: Therapeutic Control of AERD$114,202
U19 · FY2020 · AI · contact PI
Immunometabolic phenotypes in adult severe asthma and disease progression$3,419,613
U01 · FY2019 · HL
PATINA - Precision Administration of Treatment in Neutrophilic severe Asthma$481,937
UG1 · FY2019 · HL · contact PI
Project 3: Therapeutic Control of AERD$331,786
U19 · FY2019 · AI · contact PI
PATINA - Precision Administration of Treatment in Neutrophilic severe Asthma$491,467
UG1 · FY2018 · HL · contact PI
Project 3: Therapeutic Control of AERD$331,783
U19 · FY2018 · AI · contact PI
Project 3: Therapeutic Control of AERD$575,271
U19 · FY2017 · AI · contact PI
PATINA - Precision Administration of Treatment in Neutrophilic severe Asthma$421,005
UG1 · FY2017 · HL · contact PI
AMSA: ALXR/FBR Mediated Signaling in Severe Asthma$714,183
U10 · FY2016 · HL · contact PI
Project 3: Therapeutic Control of AERD$319,617
U19 · FY2016 · AI · contact PI
AMSA: ALXR/FBR Mediated Signaling in Severe Asthma$695,606
U10 · FY2015 · HL · contact PI
Therapeutic Control of Aspirin-Exacerbated Respiratory Disease$473,068
U19 · FY2015 · AI · contact PI
AsthmaNet: Brigham and Women's Hospital & Children's Hospital Boston$390,500
U10 · FY2015 · HL · contact PI
AMSA: ALXR/FBR Mediated Signaling in Severe Asthma$708,154
U10 · FY2014 · HL · contact PI
AsthmaNet: Brigham and Women's Hospital & Children's Hospital Boston$575,184
U10 · FY2014 · HL · contact PI
Therapeutic Control of Aspirin-Exacerbated Respiratory Disease$529,217
U19 · FY2014 · AI · contact PI
AsthmaNet: Brigham and Women's Hospital & Children's Hospital Boston$989,393
U10 · FY2013 · HL · contact PI
PESBART: Effects of Physical Environment and Stress in Blacks in Relation to Asth$750,000
R01 · FY2013 · HS · contact PI
AMSA: ALXR/FBR Mediated Signaling in Severe Asthma$675,025
U10 · FY2013 · HL · contact PI
Therapeutic Control of Aspirin-Exacerbated Respiratory Disease$516,764
U19 · FY2013 · AI · contact PI
Kit Inhibition in Asthma (KIA)$2,548,859
U01 · FY2012 · HL · contact PI
AsthmaNet: Brigham and Women's Hospital & Children's Hospital Boston$989,393
U10 · FY2012 · HL · contact PI
AMSA: ALXR/FBR Mediated Signaling in Severe Asthma$709,100
U10 · FY2012 · HL · contact PI
Lipoxins in Severe Asthma (LIPSA)$535,500
P50 · FY2012 · HL · contact PI
Therapeutic Control of Aspirin-Exacerbated Respiratory Disease$489,113
U19 · FY2012 · AI · contact PI
Kit Inhibition in Asthma (KIA)$2,294,684
U01 · FY2011 · HL · contact PI
BELT: Blacks & Exacerbations on LABA vs. Tiotropium$2,137,706
R01 · FY2011 · HS · contact PI
AsthmaNet: Brigham and Women's Hospital & Children's Hospital Boston$988,251
U10 · FY2011 · HL · contact PI
AMSA: ALXR/FBR Mediated Signaling in Severe Asthma$688,917
U10 · FY2011 · HL · contact PI
Lipoxins in Severe Asthma (LIPSA)$534,750
P50 · FY2011 · HL · contact PI
Therapeutic Control of Aspirin-Exacerbated Respiratory Disease$484,798
U19 · FY2011 · AI · contact PI
BELT: Blacks & Exacerbations on LABA vs. Tiotropium$7,177,459
R01 · FY2010 · HS · contact PI
Kit Inhibition in Asthma (KIA)$1,407,512
U01 · FY2010 · HL · contact PI
AsthmaNet: Brigham and Women's Hospital & Children's Hospital Boston$981,959
U10 · FY2010 · HL · contact PI
AsthmaNet: Brigham and Women's Hospital & Children's Hospital Boston$615,541
U10 · FY2009 · HL · contact PI
COUNTER-REGULATORY LIPID DERIVED SIGNALS IN SEVERE ASTHMA$3,556
M01 · FY2008 · RR · contact PI
Informative Clinical Studies in Asthma$1,938,074
U10 · FY2007 · HL · contact PI
COUNTER-REGULATORY LIPID DERIVED SIGNALS IN SEVERE ASTHMA$23,837
M01 · FY2007 · RR · contact PI
Informative Clinical Studies in Asthma$1,004,402
U10 · FY2006 · HL · contact PI
COUNTER-REGULATORY LIPID DERIVED SIGNALS IN SEVERE ASTHMA$6,594
M01 · FY2006 · RR · contact PI
Informative Clinical Studies in Asthma$1,001,474
U10 · FY2005 · HL
COUNTER REGULATORY LIPID SIGNALS IN SEVERE ASTHMA$604,890
R01 · FY2005 · HL
COUNTER-REGULATORY LIPID DERIVED SIGNALS IN SEVERE ASTHMA$2,679
M01 · FY2005 · RR
Informative Clinical Studies in Asthma$902,817
U10 · FY2004 · HL
COUNTER REGULATORY LIPID SIGNALS IN SEVERE ASTHMA$604,907
R01 · FY2004 · HL
Informative Clinical Studies in Asthma$950,576
U10 · FY2003 · HL
COUNTER REGULATORY LIPID SIGNALS IN SEVERE ASTHMA$604,925
R01 · FY2003 · HL
ASTHMA CLINICAL RESEARCH NETWORK$1,146,890
U10 · FY2002 · HL
COUNTER REGULATORY LIPID SIGNALS IN SEVERE ASTHMA$604,068
R01 · FY2002 · HL
DOSE OF INHALED CORTICOSTEROIDS WITH EQUISYSTEMIC EFFECTS (DICE)$0
M01 · FY2002 · RR
MEASURING INHALED CORTICOSTEROID EFFICACY$0
M01 · FY2002 · RR
GLUCOCORTICOID INDUCED OSTEOPENIA IN PULMONARY PATIENTS$0
M01 · FY2002 · RR
INFLAMMATORY EVENTS INITIATING AND PERPETUATING ASTHMA$1,100,198
P50 · FY2001 · HL
ASTHMA CLINICAL RESEARCH NETWORK$792,154
U10 · FY2001 · HL
COUNTER REGULATORY LIPID SIGNALS IN SEVERE ASTHMA$599,616
R01 · FY2001 · HL
DOSE OF INHALED CORTICOSTEROIDS WITH EQUISYSTEMIC EFFECTS (DICE)$0
M01 · FY2001 · RR
MEASURING INHALED CORTICOSTEROID EFFICACY$0
M01 · FY2001 · RR
GLUCOCORTICOID INDUCED OSTEOPENIA IN PULMONARY PATIENTS$0
M01 · FY2001 · RR
INFLAMMATORY EVENTS INITIATING AND PERPETUATING ASTHMA$1,632,782
P50 · FY2000 · HL
ASTHMA CLINICAL RESEARCH NETWORK$881,075
U10 · FY2000 · HL
DOSE OF INHALED CORTICOSTEROIDS WITH EQUISYSTEMIC EFFECTS (DICE)$0
M01 · FY2000 · RR
MEASURING INHALED CORTICOSTEROID EFFICACY$0
M01 · FY2000 · RR
GLUCOCORTICOID INDUCED OSTEOPENIA IN PULMONARY PATIENTS$0
M01 · FY2000 · RR